Supplementary Figure S5 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Supplementary Figure S5. Overall survival in patients with or without baseline liver metastases.
Supplementary Figure S5 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer | Synapse